code stringlengths 4 12 | description stringlengths 2 264 | codetype stringclasses 8
values | context stringlengths 160 15.5k |
|---|---|---|---|
85027 | HEMOGRAM | HCPCS | - Three-digit number reported (such as 31.2) = 31.2
- Two-digit number reported (such as 4.5) = 04.5
- Two-digit whole number reported (such as 28) = 28.0
- Single decimal position reported (such as .9) = 00.9
- One-digit whole number reported (such as 7) = 07.0
- Test result reported as 2-digits and 2 decimal places (... |
A9580 | Sodium fluoride f-18, diagnostic, per study dose, up to 30 millicuries | HCPCS | 04/12/2010: Description section revised to add the four oncologic applications of PET Scanning; Policy section revised to add indications considered medically necessary for Melanoma, Lymphoma, lung; colorectal; pancreatic; head & neck; esophageal; breast; ovarian and testicular cancers. Added indications considered med... |
A9580 | Sodium fluoride f-18, diagnostic, per study dose, up to 30 millicuries | HCPCS | Added indications considered medically necessary for differentiated thyroid and cervical cancers; added prostate cancer and cancer surveillance as investigational for all indications. Code reference section revised to add the following ICD-9 diagnosis codes to the covered codes table: 140.0 - 140.9; 141.0 - 141.9; 142.... |
A9580 | Sodium fluoride f-18, diagnostic, per study dose, up to 30 millicuries | HCPCS | Code reference section revised to add the following ICD-9 diagnosis codes to the covered codes table: 140.0 - 140.9; 141.0 - 141.9; 142.0 - 142.9; 143.0 - 143.9; 150.0 -150.9; 151.0 - 151.9, 155.1; 156.0; 156.2; 157.0 -157.9; 158.0 - 158.9; 159.0 - 159.9; 174.0 - 174.5 and 174.8 - 174.9; 175.0; 175.9; 180.0 - 180.9; 18... |
A9580 | Sodium fluoride f-18, diagnostic, per study dose, up to 30 millicuries | HCPCS | Moved HCPCS Code A9580 from non-covered to covered table. 10/05/2010: Policy reviewed; policy statement unchanged. Removed the following ICD-9 codes from the Covered Codes table to be consistent with the policy statement: 151.0-151.9, 152.0-152.9, 155.0-155.2, 156.0-156.9, 158.0-158.9, 159.0, 159.1, 159.8, 159.9, 194.0... |
95027 | PR INTRACUTANEOUS TESTS W/ALLERGENIC XTRCS AIRBORNE | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY9/1992: Issued
2/1997: Revised: Limitation on number of tests; denial of repeat testing except in rare circumstances; moved two tests (nasal and conjunctival challenge) ... |
95078 | Provocative testing | HCPCS | The coverage guidelines outlined in the Medical Policy Manual should not be used in lieu of the Member's specific benefit plan language. POLICY HISTORY9/1992: Issued
2/1997: Revised: Limitation on number of tests; denial of repeat testing except in rare circumstances; moved two tests (nasal and conjunctival challenge) ... |
95027 | PR INTRACUTANEOUS TESTS W/ALLERGENIC XTRCS AIRBORNE | HCPCS | POLICY HISTORY9/1992: Issued
2/1997: Revised: Limitation on number of tests; denial of repeat testing except in rare circumstances; moved two tests (nasal and conjunctival challenge) to Investigational list. 4/28/00 See clarification under POLICY. 5/23/2001: Code reference section updated; ICD-9 diagnosis codes 117.3, ... |
95078 | Provocative testing | HCPCS | POLICY HISTORY9/1992: Issued
2/1997: Revised: Limitation on number of tests; denial of repeat testing except in rare circumstances; moved two tests (nasal and conjunctival challenge) to Investigational list. 4/28/00 See clarification under POLICY. 5/23/2001: Code reference section updated; ICD-9 diagnosis codes 117.3, ... |
95015 | Id allergy titrate-drug/bug | HCPCS | POLICY HISTORY9/1992: Issued
2/1997: Revised: Limitation on number of tests; denial of repeat testing except in rare circumstances; moved two tests (nasal and conjunctival challenge) to Investigational list. 4/28/00 See clarification under POLICY. 5/23/2001: Code reference section updated; ICD-9 diagnosis codes 117.3, ... |
95027 | PR INTRACUTANEOUS TESTS W/ALLERGENIC XTRCS AIRBORNE | HCPCS | 4/28/00 See clarification under POLICY. 5/23/2001: Code reference section updated; ICD-9 diagnosis codes 117.3, 496.7, and 708.3 deleted; non-covered codes table added
11/2001: Reviewed by MPAC; SDET or Rinkel Method changed to covered
2/11/2002: Investigational definition added
4/18/2002: Type of Service and Place of ... |
95078 | Provocative testing | HCPCS | 4/28/00 See clarification under POLICY. 5/23/2001: Code reference section updated; ICD-9 diagnosis codes 117.3, 496.7, and 708.3 deleted; non-covered codes table added
11/2001: Reviewed by MPAC; SDET or Rinkel Method changed to covered
2/11/2002: Investigational definition added
4/18/2002: Type of Service and Place of ... |
95015 | Id allergy titrate-drug/bug | HCPCS | 4/28/00 See clarification under POLICY. 5/23/2001: Code reference section updated; ICD-9 diagnosis codes 117.3, 496.7, and 708.3 deleted; non-covered codes table added
11/2001: Reviewed by MPAC; SDET or Rinkel Method changed to covered
2/11/2002: Investigational definition added
4/18/2002: Type of Service and Place of ... |
95027 | PR INTRACUTANEOUS TESTS W/ALLERGENIC XTRCS AIRBORNE | HCPCS | 5/23/2001: Code reference section updated; ICD-9 diagnosis codes 117.3, 496.7, and 708.3 deleted; non-covered codes table added
11/2001: Reviewed by MPAC; SDET or Rinkel Method changed to covered
2/11/2002: Investigational definition added
4/18/2002: Type of Service and Place of Service deleted
6/5/2002: Code Reference... |
95078 | Provocative testing | HCPCS | 5/23/2001: Code reference section updated; ICD-9 diagnosis codes 117.3, 496.7, and 708.3 deleted; non-covered codes table added
11/2001: Reviewed by MPAC; SDET or Rinkel Method changed to covered
2/11/2002: Investigational definition added
4/18/2002: Type of Service and Place of Service deleted
6/5/2002: Code Reference... |
95015 | Id allergy titrate-drug/bug | HCPCS | 5/23/2001: Code reference section updated; ICD-9 diagnosis codes 117.3, 496.7, and 708.3 deleted; non-covered codes table added
11/2001: Reviewed by MPAC; SDET or Rinkel Method changed to covered
2/11/2002: Investigational definition added
4/18/2002: Type of Service and Place of Service deleted
6/5/2002: Code Reference... |
20694 | Rmvl ext fixj sys under anes | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
21206 | Reconstruct upper jaw bone | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
42200 | Reconstruct cleft palate | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
D6199 | PR UNSPEC IMPLANT PROCEDURE BY REPORT | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
21196 | Reconst lwr jaw w/fixation | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
21247 | Reconstruct lower jaw bone | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
D8999 | PR UNS ORTHODONTIC PROCEDURE BY REPORT | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
20693 | PR ADJUSTMENT/REVJ XTRNL FIXATION SYSTEM REQ ANES | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
D8010 | PR LTD ORTHODONT TX PRIMARY DENTITION | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
30462 | Revision of nose | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
21110 | PR APPL INTERDENTAL FIXATION DEVICE NON-FX/DISLC | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
0232T | Njx platelet plasma | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
21210 | PR GRAFT BONE NASAL/MAXILLARY/MALAR AREAS | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
20696 | PR APP MLTPLN UNI XTRNL FIX STRTCTC ADJMT 1ST&SUBSQ | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
30400 | Reconstruction of nose | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
21120 | Reconstruction of chin | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
20692 | PR APPLICATION MULTIPLANE EXTERNAL FIXATION SYSTEM | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
38220 | PR DIAGNOSTIC BONE MARROW ASPIRATIONS | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
D7949 | Reconstruct midface w/graft | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
42225 | Reconstruct cleft palate | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
20697 | PR APP MLTPLN UNI XTRNL FIX STRTCTC ADJMT EXCHANGE | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
D6010 | PR SURG PLCMT IMPL BODY: ENDOSTEAL | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
S9055 | Procuren or other growth fac | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
D7946 | Reconstruction maxilla total | HCPCS | The authors concluded that injection of rhBMP-2 into regenerated bone after a distraction osteogenesis procedure significantly increased bone volume in the dento-alveolar distraction site and improved both the width and height of the alveolar ridge and increased the bone density. These preliminary findings from a canin... |
20694 | Rmvl ext fixj sys under anes | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
21206 | Reconstruct upper jaw bone | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
42200 | Reconstruct cleft palate | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
D6199 | PR UNSPEC IMPLANT PROCEDURE BY REPORT | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
21196 | Reconst lwr jaw w/fixation | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
21247 | Reconstruct lower jaw bone | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
D8999 | PR UNS ORTHODONTIC PROCEDURE BY REPORT | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
20693 | PR ADJUSTMENT/REVJ XTRNL FIXATION SYSTEM REQ ANES | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
D8010 | PR LTD ORTHODONT TX PRIMARY DENTITION | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
30462 | Revision of nose | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
21110 | PR APPL INTERDENTAL FIXATION DEVICE NON-FX/DISLC | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
0232T | Njx platelet plasma | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
21210 | PR GRAFT BONE NASAL/MAXILLARY/MALAR AREAS | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
20696 | PR APP MLTPLN UNI XTRNL FIX STRTCTC ADJMT 1ST&SUBSQ | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
30400 | Reconstruction of nose | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
21120 | Reconstruction of chin | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
20692 | PR APPLICATION MULTIPLANE EXTERNAL FIXATION SYSTEM | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
38220 | PR DIAGNOSTIC BONE MARROW ASPIRATIONS | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
D7949 | Reconstruct midface w/graft | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
42225 | Reconstruct cleft palate | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
20697 | PR APP MLTPLN UNI XTRNL FIX STRTCTC ADJMT EXCHANGE | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
D6010 | PR SURG PLCMT IMPL BODY: ENDOSTEAL | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
S9055 | Procuren or other growth fac | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
D7946 | Reconstruction maxilla total | HCPCS | These preliminary findings from a canine model need to be examined in human subjects. |CPT Codes / HCPCS Codes / ICD-10 Codes|
|Information in the [brackets] below has been added for clarification purposes. Codes requiring a 7th character are represented by "+":|
|ICD-10 codes will become effective as of October 1, 201... |
1745 | Thoracoscopic robotic assisted procedure | ICD | The Monmouth and Ocean County breast cancer death rate in the past two decades was 20.1% above the U.S., but 4.5% below for all causes other than cancer (Table 5). These differences are consistent for young, middle-aged, and older women. Mortality, Monmouth/Ocean Counties vs. U.S.
From Cancer and From All Other Causes,... |
1745 | Thoracoscopic robotic assisted procedure | ICD | These differences are consistent for young, middle-aged, and older women. Mortality, Monmouth/Ocean Counties vs. U.S.
From Cancer and From All Other Causes, 1985-2003
|All Cancers||Cancer||% Local is +/- U.S.|
|Age 0-14||133||+13.4||– 31.7|
|Age 15-44||1745||+12.0||– 16.4|
|All- Whites||51430||+10.7||– 3.8|
|All- Black... |
1745 | Thoracoscopic robotic assisted procedure | ICD | Mortality, Monmouth/Ocean Counties vs. U.S.
From Cancer and From All Other Causes, 1985-2003
|All Cancers||Cancer||% Local is +/- U.S.|
|Age 0-14||133||+13.4||– 31.7|
|Age 15-44||1745||+12.0||– 16.4|
|All- Whites||51430||+10.7||– 3.8|
|All- Blacks||2478||+ 5.3||+ 0.4|
|Breast Cancer (white females)|
|Age 25-44||263||+1... |
00216 | ANESTH HEAD VESSEL SURGERY | CPT | For this procedure, we’d code 35471 for “transluminal balloon angioplasty, percutaneous; renal or other visceral artery,” and we’d add the modifier -66 for “surgical team.” So we’d end up with 35471-66. Source: http://www.medicalbillingandcoding.org/cpt-modifiers/
Physical Status Modifier (For Anesthesia)
Anesthesia pr... |
00216 | ANESTH HEAD VESSEL SURGERY | CPT | These codes are:
- P1 – a normal, healthy patient
- P2 – a patient with mild systemic disease
- P3 – a patient with severe systemic disease
- P4 – a patient with severe systemic disease that is a constant threat to life
- P5 – a moribund patient who is not expected to survive without the operation
- P6 – a declared bra... |
00216 | ANESTH HEAD VESSEL SURGERY | CPT | Let’s return to that angioplasty example. The patient needs to be anesthetized before undergoing this procedure, so we turn to the Anesthesia section of the CPT codebook and find the code 00216 for “vascular procedures.” Now, kidney problems notwithstanding, our patient is in good health, so we’d add the –P1 modifier t... |
00216 | ANESTH HEAD VESSEL SURGERY | CPT | The patient needs to be anesthetized before undergoing this procedure, so we turn to the Anesthesia section of the CPT codebook and find the code 00216 for “vascular procedures.” Now, kidney problems notwithstanding, our patient is in good health, so we’d add the –P1 modifier to this anesthesia code, and end up with 00... |
90674 | HC CCIIV4 VACCINE PRESERVATIVE FREE 0.5 ML IM USE | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90653 | HC FLU VACCINE ADJUVANT IM | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
9065 | Argatroban esrd dialysis | APC | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
9067 | Lutetium lu 177 dotatat t | APC | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90662 | INFLUENZA VIRUS VACCINE (IIV), SPLIT VIRUS, PRESERVATIVE FREE, ENHANCED IMMUNOGENICITY VIA INCREASED ANTIGEN CONTENT, FOR INTRAMUSCULAR USE | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90685 | HC IIV4 VACC PRSRV FREE 0.25 ML DOS FOR IM USE | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90656 | HC IIV3 VACC PRESERVATIVE FREE 0.5 ML DOSAGE IM USE | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
9075 | Inj, kovaltry, 1 i.u. | APC | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
Q2035 | PR AFLURIA VACC, 3 YRS & >, IM | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90688 | HC IIV4 VACC SPLIT VIRUS 0.5 ML DOS FOR IM USE | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90687 | Iiv4 vaccine splt 0.25 ml im | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90756 | PR CCIIV4 VACCINE ANTIBIOTIC FREE 0.5 ML DOS IM USE | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
G0008 | PR ADMIN INFLUENZA VIRUS VAC | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
9068 | Smallpox&monkeypox vac 0. | APC | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90689 | HC IIV4 VACC INACTIVATED PRSRV FR 0.25ML DOS IM US | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90686 | INFLUENZA VIRUS VACCINE, QUADRIVALENT (IIV4), SPLIT VIRUS, PRESERVATIVE FREE, 0.5 ML DOSAGE, FOR INTRAMUSCULAR USE | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90682 | HC RIV4 VACC RECOMBINANT DNA PRSRV ANTIBIO FREE IM | HCPCS | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
2035 | Auto cell process sys | APC | The influenza A (H3N2) and both influenza B reference viruses will be cell-derived, and the influenza A (H1N1) will be egg-derived. - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administr... |
90674 | HC CCIIV4 VACCINE PRESERVATIVE FREE 0.5 ML IM USE | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90653 | HC FLU VACCINE ADJUVANT IM | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
9065 | Argatroban esrd dialysis | APC | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
9067 | Lutetium lu 177 dotatat t | APC | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90662 | INFLUENZA VIRUS VACCINE (IIV), SPLIT VIRUS, PRESERVATIVE FREE, ENHANCED IMMUNOGENICITY VIA INCREASED ANTIGEN CONTENT, FOR INTRAMUSCULAR USE | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90685 | HC IIV4 VACC PRSRV FREE 0.25 ML DOS FOR IM USE | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90656 | HC IIV3 VACC PRESERVATIVE FREE 0.5 ML DOSAGE IM USE | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
9075 | Inj, kovaltry, 1 i.u. | APC | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
Q2035 | PR AFLURIA VACC, 3 YRS & >, IM | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90688 | HC IIV4 VACC SPLIT VIRUS 0.5 ML DOS FOR IM USE | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
90687 | Iiv4 vaccine splt 0.25 ml im | HCPCS | - Intradermal flu vaccines will not be available. - The age recommendation for “Fluarix Quadrivalent” and for Afluria Quadrivalent was changed to be consistent with Food and Drug Administration (FDA) – approved labeling:
- For Fluarix Quadrivalent – from 3 years old and older to 6 months and older
- For Afluria Quadriv... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.